Jaume Capdevila, Nicola Fazio, Carlos Lopez, Alexandre Teulé, Juan W Valle, Salvatore Tafuto, Ana Custodio, Nicholas Reed, Markus Raderer, Enrique Grande, Rocio Garcia-Carbonero, Paula Jimenez-Fonseca, Jorge Hernando, Alberto Bongiovanni, Francesca Spada, Vicente Alonso, Lorenzo Antonuzzo, Andrea Spallanzani, Alfredo Berruti, Adelaida La Casta, Isabel Sevilla, Patrizia Kump, Dario Giuffrida, Xavier Merino, Lorena Trejo, Pablo Gajate, Ignacio Matos, Angela Lamarca, Toni Ibrahim
PURPOSE: Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression to targeted agents (TAs). We investigated the efficacy and safety of lenvatinib in patients with previously treated advanced GEP-NETs. PATIENTS AND METHODS: This was a multicenter, single-arm, open-label, phase II trial with two parallel cohorts (ClinicalTrials.gov identifier: NCT02678780) involving 21 institutions in 4 European countries...
July 10, 2021: Journal of Clinical Oncology